Evaluating the interstitial lung disease multidisciplinary meeting: A survey of expert centres

BMC Pulmonary Medicine

Volumn 16, Issue 1, 2016, Pages

  Jo, Helen E ^a,b   Corte, Tamera J ^a,b   Moodley, Yuben ^c,d,e   Levin, Kovi ^f   Westall, Glen ^f,g   Hopkins, Peter ^h,i   Chambers, Daniel ^h,i   Glaspole, Ian ^f,g  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d FIONA STANLEY HOSPITAL   (Australia)

^e Institute for Respiratory Health   (Australia)

^f ALFRED HOSPITAL   (Australia)

^g MONASH UNIVERSITY   (Australia)

^h THE PRINCE CHARLES HOSPITAL   (Australia)

ⁱ UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Diagnosis; Idiopathic pulmonary fibrosis; Interstitial lung disease; Multidisciplinary meeting

Indexed keywords

ARTICLE; AUSTRALIA; DATA ANALYSIS; DOCUMENTATION; EUROPE; HUMAN; INTERNET; INTERSTITIAL LUNG DISEASE; MULTIDISCIPLINARY MEETING; NORTH AMERICA; OUTCOME ASSESSMENT; PATIENT CARE; QUESTIONNAIRE; CANADA; DISEASE MANAGEMENT; FRANCE; IMMUNOLOGY; INTERDISCIPLINARY COMMUNICATION; LUNG DISEASES, INTERSTITIAL; NURSING STAFF; ORGANIZATION; ORGANIZATION AND MANAGEMENT; PALLIATIVE THERAPY; PATHOLOGY; PULMONOLOGY; RADIOLOGY; RHEUMATOLOGY; THORAX SURGERY; UNITED KINGDOM; UNITED STATES;

ALLERGY AND IMMUNOLOGY; AUSTRALIA; CANADA; CONGRESSES AS TOPIC; DISEASE MANAGEMENT; FRANCE; HUMANS; INTERDISCIPLINARY COMMUNICATION; LUNG DISEASES, INTERSTITIAL; NURSING STAFF; PALLIATIVE MEDICINE; PATHOLOGY, CLINICAL; PATIENT CARE TEAM; PULMONARY MEDICINE; RADIOLOGY; RHEUMATOLOGY; SURVEYS AND QUESTIONNAIRES; THORACIC SURGERY; UNITED KINGDOM; UNITED STATES;

EID: 84957956038     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/s12890-016-0179-3     Document Type: Article

References (28)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277-304.
2. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48.
3. King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164(7):1171-81.
4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82.
5. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-92.
6. Flaherty KR, King Jr TE, Raghu G, Lynch 3rd JP, Colby TV, Travis WD, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904-10.
7. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788-824.
8. Wells AU, Hirani N. Interstitial lung disease guideline. Thorax. 2008;63 Suppl 5:v1-v58.
9. Flaherty KR, Andrei AC, King Jr TE, Raghu G, Colby TV, Wells A, et al. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis? Am J Respir Crit Care Med. 2007;175(10):1054-60.
10. Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. New Engl J Med. 2012;366(21):1968-1977.
11. Merlin T, Lehman S, Hiller JE, Ryan P. The "linked evidence approach" to assess medical tests: a critical analysis. Int J Technol Assess Health Care. 2013;29(3):343-50.
12. Yoshida K, Ando M, Sakata T, Araki S. Prevention of summer-type hypersensitivity pneumonitis: effect of elimination of Trichosporon cutaneum from the patients' homes. Arch Environ Health. 1989;44(5):317-22.
13. Selman M, Pardo A, King Jr TE. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med. 2012;186(4):314-24.
14. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. New Engl J Med. 2006;354(25):2655-66.
15. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000;132(12):947-54.
16. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. MYcophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease*. Chest. 2006;130(1):30-6.
17. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150-5.
18. Douglas WW, Tazelaar HD, Hartman TE, Hartman RP, Decker PA, Schroeder DR, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164(7):1182-5.
19. Vij R, Strek ME. Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest. 2013;143(3):814-24.
20. Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjögren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154(3):794-9.
21. Keating D, Levvey B, Kotsimbos T, Whitford H, Westall G, Williams T, et al. Lung transplantation in pulmonary fibrosis: challenging early outcomes counterbalanced by surprisingly good outcomes beyond 15 years. Transplant Proc. 2009;41(1):289-91.
22. Raghu G, Rochwerg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3-e19.
23. Ratner M. Landmark approvals in idiopathic pulmonary fibrosis. Nat Biotechnol. 2014;32(11):1069-70.
24. Thomeer M, Demedts M, Behr J, Buhl R, Costabel U, Flower CD, et al. Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis. Eur Respir J. 2008;31(3):585-91.
25. Aziz ZA, Wells AU, Hansell DM, Bain GA, Copley SJ, Desai SR, et al. HRCT diagnosis of diffuse parenchymal lung disease: inter-observer variation. Thorax. 2004;59(6):506-11.
26. Nicholson AG, Addis BJ, Bharucha H, Clelland CA, Corrin B, Gibbs AR, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax. 2004;59(6):500-5.
27. Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, et al. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014;108(7):1023-30.
28. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-9.